SG Americas Securities LLC Buys 240,039 Shares of Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

SG Americas Securities LLC lifted its stake in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 1,017.7% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 263,625 shares of the company’s stock after acquiring an additional 240,039 shares during the quarter. SG Americas Securities LLC owned about 0.20% of Centessa Pharmaceuticals worth $6,593,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. China Universal Asset Management Co. Ltd. raised its stake in shares of Centessa Pharmaceuticals by 4.8% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 19,181 shares of the company’s stock valued at $252,000 after acquiring an additional 870 shares in the last quarter. HighVista Strategies LLC boosted its position in Centessa Pharmaceuticals by 4.3% during the second quarter. HighVista Strategies LLC now owns 40,684 shares of the company’s stock worth $535,000 after purchasing an additional 1,664 shares during the period. Legal & General Group Plc grew its holdings in Centessa Pharmaceuticals by 3.5% during the third quarter. Legal & General Group Plc now owns 101,693 shares of the company’s stock valued at $2,464,000 after purchasing an additional 3,437 shares during the last quarter. Tudor Investment Corp ET AL grew its holdings in Centessa Pharmaceuticals by 13.7% during the third quarter. Tudor Investment Corp ET AL now owns 57,810 shares of the company’s stock valued at $1,402,000 after purchasing an additional 6,959 shares during the last quarter. Finally, DNB Asset Management AS bought a new position in shares of Centessa Pharmaceuticals in the third quarter valued at approximately $218,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

Insider Buying and Selling

In other Centessa Pharmaceuticals news, insider Iqbal J. Hussain sold 38,951 shares of the business’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $25.15, for a total value of $979,617.65. Following the sale, the insider owned 57,645 shares of the company’s stock, valued at $1,449,771.75. The trade was a 40.32% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Karen M. Anderson sold 120,029 shares of the stock in a transaction on Friday, March 13th. The shares were sold at an average price of $26.25, for a total transaction of $3,150,761.25. Following the completion of the transaction, the insider owned 62,085 shares of the company’s stock, valued at approximately $1,629,731.25. This represents a 65.91% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 349,073 shares of company stock valued at $9,429,412 over the last ninety days. 7.09% of the stock is owned by company insiders.

Centessa Pharmaceuticals Stock Up 44.0%

Shares of CNTA opened at $39.72 on Wednesday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 10.57 and a current ratio of 10.56. The company has a 50-day simple moving average of $26.29 and a 200-day simple moving average of $25.24. Centessa Pharmaceuticals PLC Sponsored ADR has a 52 week low of $9.60 and a 52 week high of $40.26. The firm has a market capitalization of $5.80 billion, a P/E ratio of -21.70 and a beta of 1.55.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings results on Tuesday, March 31st. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.10). On average, equities research analysts expect that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 earnings per share for the current year.

Analyst Upgrades and Downgrades

CNTA has been the subject of a number of analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research note on Wednesday, January 21st. TD Cowen reiterated a “buy” rating on shares of Centessa Pharmaceuticals in a report on Wednesday, January 14th. Oppenheimer boosted their target price on shares of Centessa Pharmaceuticals from $40.00 to $62.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 10th. Chardan Capital reaffirmed a “buy” rating and issued a $30.00 price target on shares of Centessa Pharmaceuticals in a research report on Friday, January 2nd. Finally, Wolfe Research reiterated a “peer perform” rating on shares of Centessa Pharmaceuticals in a research note on Tuesday. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $40.00.

Trending Headlines about Centessa Pharmaceuticals

Here are the key news stories impacting Centessa Pharmaceuticals this week:

• Positive Sentiment: Eli Lilly agreed to buy Centessa for $38 per share in cash plus a potential contingent value right (CVR) worth up to $9 per share, valuing the deal at roughly $6.3B up front and up to $7.8B including milestones; the transaction is framed as an expansion of Lilly’s neuroscience/sleep?medicine pipeline. Eli Lilly to buy Centessa Pharma in $6.3 billion deal
• Positive Sentiment: Deal terms include the $38 cash upfront plus CVR milestones (up to $9) — investors are pricing some or all of the CVR into CNTA shares, which helps explain the stock trading above the $38 cash figure. Eli Lilly to acquire Centessa in $6.3B deal to expand neuroscience portfolio
• Positive Sentiment: Unusual options activity: large jump in call buying (nearly 3,000 calls traded, a ~472% spike vs. normal), signaling short?term bullish speculation or hedging around the deal news.
• Neutral Sentiment: Analysts have mostly left ratings unchanged (Wolfe Research “peer perform”, Needham “hold”), suggesting the deal changes valuation more than near?term fundamentals. Analyst coverage updates
• Neutral Sentiment: Trading metrics: unusually high share volume and CNTA trading near its 12?month high, driven by the acquisition announcement and attendant positioning flows.
• Negative Sentiment: Shareholder litigation/investigations have been filed or announced (Ademi Firm and Halper Sadeh LLC) alleging Centessa shareholders may not be getting a fair price, which could lead to legal review, delay or pressure on deal terms. Shareholder Alert: The Ademi Firm investigates whether Centessa Pharmaceuticals plc is obtaining a Fair Price for Public Shareholders CNTA Stock Alert: Halper Sadeh LLC is Investigating Whether Centessa Pharmaceuticals plc is Obtaining a Fair Price for its Shareholders

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc is a global clinical?stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision?making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.